

# Safety and Efficacy of Edoxaban and Rivaroxaban to Cerebral Venous Thrombosis in Chinese Patients

NCT06947707

---

**Status** RECRUITING  
**Sponsor** Xuanwu Hospital, Beijing  
**Enrollment** 1,486 participants

## Key Eligibility Criteria

---

### Inclusion (5)

- Patient aged from 18 to 80 years and no gender preference;
- Diagnosis of CVT as confirmed on MRBTI/MRV or CT/CTV or DSA;
- Acute or subacute CVT from onset to door within 4 weeks;
- The treating clinician irrelevant to the study is of the opinion that the patient is appropriate for edoxaban or rivaroxaban;
- Patient or legally authorized representative is able to give written informed consent.

### Exclusion (14)

- Patient refuse to take edoxaban or rivaroxaban to treat CVT;
- Pregnancy or breastfeeding women at the time of enrollment, or women who plan to get pregnant during study;
- Patient is anticipated to require invasive procedure (e.g. thrombectomy, hemicraniectomy) prior to initiation of oral anticoagulation;
- CVT secondary to central nervous system infection or severe head trauma;
- It is in the proliferative stage of malignant tumors currently or within 6 months of diagnosis;
- ... and 9 more (see full listing online)

## Locations (1 total)

---

Xuanwu Hospital, Capital Medical University, Beijing, Beijing Municipality, China